10-Q: Regen BioPharma Reports Q3 2024 Results, Cites Ongoing Losses and Need for Additional Financing

Regen BioPharma's Q3 2024 report reveals continued operating losses and a reliance on equity financing, highlighting the company's ongoing need for capital.

Summary

• Regen BioPharma reported a net loss of $130,120 for the quarter ended June 30, 2024, compared to a net loss of $99,218 for the same period in 2023.
• The company's operating loss for the quarter was $107,966, compared to $85,155 in the prior year.
• Revenues remained consistent at $59,065 for both the current and prior year quarter.
• For the nine months ended June 30, 2024, the net loss was $602,353, a significant decrease compared to the net income of $1,481,534 for the same period in 2023, which was primarily due to a large unrealized gain on investment securities.
• The company's cash position decreased from $121,037 on September 30, 2023, to $61,849 on June 30, 2024.
• The company has significant current liabilities of $5,327,862, including accounts payable, notes payable, convertible notes payable, derivative liability, unearned income, and accrued expenses.
• Regen Biopharma is relying on an equity line agreement with Coventry Enterprises to raise capital, having sold 866,712 common shares for $535,560 during the nine months ended June 30, 2024.
• The company has issued a stock dividend of two shares of Series A Preferred Stock for every one share of common and preferred stock held as of June 20, 2024.

Sentiment

Score: 3

Explanation: The document indicates a weak financial position with significant losses, decreasing cash reserves, and reliance on equity financing. The company's investment securities have also significantly decreased in value. The company states it will not be able to satisfy its cash requirements over the next twelve months and shall be required to seek additional financing. These factors contribute to a negative sentiment.

Positives

• Revenues remained consistent at $59,065 for the quarter ended June 30, 2024, compared to the same period in 2023.
• The company has an equity line agreement in place to provide a potential source of funding.

Negatives

• The company experienced a significant decrease in cash, from $121,037 to $61,849.
• The company's investment securities decreased in value by 92.3% during the nine months ended June 30, 2024.
• The company has a large amount of current liabilities totaling $5,327,862.
• The company's net loss for the nine months ended June 30, 2024, was $602,353, a significant decrease compared to the net income of $1,481,534 for the same period in 2023.
• The company states it will not be able to satisfy its cash requirements over the next twelve months and shall be required to seek additional financing.

Risks

• The company's ability to continue as a going concern is dependent on its ability to obtain additional financing and achieve profitability.
• The company is in the early stages of development of its proposed products and therapies and will require FDA approval to market any products.
• The company's reliance on an equity line agreement for financing may dilute existing shareholders.
• The company has significant liabilities, including convertible notes, which could impact its financial stability.
• The company's investment securities have significantly decreased in value.

Future Outlook

The company states it will not be able to satisfy its cash requirements over the next twelve months and shall be required to seek additional financing. The company is relying on an equity line agreement with Coventry Enterprises to raise capital.

Management Comments

• The company's Principal Executive Officer and Principal Financial Officer have concluded that the company's disclosure controls and procedures are effective at a reasonable assurance level.
• The company's management believes that there were no changes to the company's internal controls over financial reporting that have been materially affected.

Industry Context

Regen Biopharma is a small biotechnology company focused on developing regenerative medical applications. The company's financial results reflect the challenges faced by early-stage biotech companies, including high research and development costs, reliance on external funding, and the need for regulatory approvals. The company's focus on NR2F6 is a specific area of research within the broader oncology and autoimmune disease fields.

Comparison to Industry Standards

• Regen Biopharma's financial performance is typical of early-stage biotech companies that are pre-revenue or have limited revenue streams.
• The company's reliance on equity financing is common in the biotech industry, where significant capital is required for research and development.
• The company's operating and net losses are consistent with other companies in the development phase of drug discovery and clinical trials.
• The company's cash burn rate is a concern, as it is rapidly depleting its cash reserves.
• The company's derivative liability related to convertible notes is a common issue for companies that have used convertible debt as a source of financing.
• The company's valuation of its investment securities is subject to market fluctuations and the performance of the underlying assets, which is a risk factor for companies with significant investments in other entities.

Related Party Transactions

• The company has related party transactions with Zander Therapeutics, Inc., including a license agreement and notes payable.
• The company has related party transactions with David Koos, including notes payable and a sublease agreement.
• The company has related party transactions with Dr. Brian Koos, including payments for services.

Stakeholder Impact

• Shareholders face the risk of dilution due to the company's reliance on equity financing.
• Employees may be impacted by the company's financial instability.
• Customers and suppliers may be impacted by the company's ability to continue operations.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to continue development of its proposed products and therapies.
• The company needs to seek FDA approval to market any products.
• The company needs to manage its liabilities and expenses.

Key Dates

Keywords

Regen BioPharma, Biotechnology, Financial Results, Quarterly Report, Equity Financing, Convertible Notes, Operating Loss, Net Loss, Preferred Stock, NR2F6, FDA Approval, Going Concern